TPM0 Stock Chart & Stats
€8.93
€0.39(4.59%)
At close: 4:00 PM EDT
€8.93
€0.39(4.59%)
Day’s Range― - ―
52-Week Range€8.13 - €32.30
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€181.82M
Enterprise Value€37.31
Total Cash (Recent Filing)€176.23M
Total Debt (Recent Filing)€1.27M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Nov 09, 2026EPS Estimate
-2.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.24
Shares Outstanding17,151,024
10 Day Avg. Volume16
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.54
Price to Sales (P/S)10.14
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.82Price Target Upside267.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-8.83
Revenue Forecast (FY)€30.06M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low debt and meaningful equity provide durable financial flexibility to support commercialization, clinical programs, and near-term operational needs. This reduces solvency/refinancing risk versus peers and gives management optionality on timing of additional raises or partnering decisions if revenues evolve.
Successful TONMYA Commercial LaunchRapid quarter-over-quarter sales and strong refill dynamics indicate initial prescriber adoption and patient retention, forming a durable commercial foundation. Combined with planned salesforce expansion and growing payer coverage, these trends support a sustainable revenue base if access and gross-to-net stabilize.
Pipeline Regulatory ProgressRegulatory alignment and a clear Phase II plan materially de-risk the TNX-4800 program versus earlier-stage projects. A well‑defined adaptive field study and on‑track investigational product manufacturing enhance the program's development credibility and its potential to become a first-in-class preventive therapy.
Bears Say
Negative Cash Generation & Short RunwaySustained negative operating and free cash flow means the company must rely on external financing to fund operations and growth. A cash runway into early Q2'27 increases near‑term financing risk and may force dilutive equity raises or constrain commercial and development investments if market conditions tighten.
Persistent Losses And Weak ProfitabilityRevenue growth is from a low base while the cost structure remains far larger than sales, producing severely negative margins and returns. This structural profitability gap risks continued equity erosion and limits the company's ability to self‑fund pipeline expansion absent sustained commercial scale or partner deals.
Event-Rate / Enrollment Risk For TNX-4800The adaptive field study's success depends on sufficient Lyme infection events in the placebo arm; lower attack rates would lengthen enrollment and delay efficacy readouts. Such timeline uncertainty raises program execution risk, increases development costs, and could push commercialization and partnership timelines materially later.
Tonix Pharma News
TPM0 FAQ
What was Tonix Pharma’s price range in the past 12 months?
Tonix Pharma lowest stock price was €8.13 and its highest was €32.30 in the past 12 months.
What is Tonix Pharma’s market cap?
Tonix Pharma’s market cap is €181.82M.
When is Tonix Pharma’s upcoming earnings report date?
Tonix Pharma’s upcoming earnings report date is Nov 09, 2026 which is in 79 days.
How were Tonix Pharma’s earnings last quarter?
Tonix Pharma released its earnings results on Aug 10, 2026. The company reported -€2.115 earnings per share for the quarter, beating the consensus estimate of -€2.29 by €0.175.
Is Tonix Pharma overvalued?
According to Wall Street analysts Tonix Pharma’s price is currently Undervalued.
Does Tonix Pharma pay dividends?
Tonix Pharma does not currently pay dividends.
What is Tonix Pharma’s EPS estimate?
Tonix Pharma’s EPS estimate is -2.15.
How many shares outstanding does Tonix Pharma have?
Tonix Pharma has 17,151,024 shares outstanding.
What happened to Tonix Pharma’s price movement after its last earnings report?
Tonix Pharma reported an EPS of -€2.115 in its last earnings report, beating expectations of -€2.29. Following the earnings report the stock price went up 7.287%.
Which hedge fund is a major shareholder of Tonix Pharma?
Currently, no hedge funds are holding shares in DE:TPM0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tonix Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.82 (267.52% Upside)
€32.82 (267.52% Upside)
Blogger Sentiment
Bullish
DE:TPM0 Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €114.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.62%
Trailing 12-Months
Company Description
Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
TPM0 Company Deck
TPM0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial momentum for TONMYA with strong near-term sales growth, improving prescription/refill metrics, expanding payer coverage, and concrete clinical progress on two mid-stage programs (TNX-102 SL for MDD and TNX-4800 for Lyme prevention). These operational positives are tempered by materially higher R&D and SG&A expenses, a limited cash runway into early Q2 2027 (requiring subsequent equity proceeds), ongoing gross-to-net and access variability, and event-driven risk for the TNX-4800 study that could delay readouts. Overall, the company demonstrates strong product and pipeline traction but faces near-term financial and trial-enrollment risks that warrant monitoring.View all DE:TPM0 earnings summariesTPM0 Stock 12 Month Forecast
Average Price Target
€32.82
▲(267.52% Upside)
Technical Analysis
Protalix
―
Fate Therapeutics
―
Avalo Therapeutics
―
Forte Biosciences
―
Innate Pharma
―